Parabilis Medicines Statistics
Total Valuation
PBLS has a market cap or net worth of $3.69 billion. The enterprise value is $3.34 billion.
Important Dates
The next estimated earnings date is Tuesday, August 18, 2026, before market open.
| Earnings Date | Aug 18, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
PBLS has 127.34 million shares outstanding.
| Current Share Class | 125.76M |
| Shares Outstanding | 127.34M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +1.61% |
| Owned by Insiders (%) | 0.01% |
| Owned by Institutions (%) | 25.04% |
| Float | 96.81M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 14.81 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio History Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.12, with a Debt / Equity ratio of 0.22.
| Current Ratio | 6.12 |
| Quick Ratio | 6.07 |
| Debt / Equity | 0.22 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -110.33 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | -47.32% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.45M |
| Employee Count | 145 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | n/a |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | n/a |
| Average Volume (20 Days) | 1,486,622 |
Short Selling Information
The latest short interest is 1.12 million, so 0.88% of the outstanding shares have been sold short.
| Short Interest | 1.12M |
| Short Previous Month | n/a |
| Short % of Shares Out | 0.88% |
| Short % of Float | 1.15% |
| Short Ratio (days to cover) | 0.47 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -156.12M |
| Pretax Income | -152.88M |
| Net Income | -209.71M |
| EBITDA | -153.67M |
| EBIT | -156.12M |
| Earnings Per Share (EPS) | -$67.09 |
Full Income Statement Balance Sheet
The company has $329.04 million in cash and $53.15 million in debt, giving a net cash position of $275.89 million or $2.17 per share.
| Cash & Cash Equivalents | 329.04M |
| Total Debt | 53.15M |
| Net Cash | 275.89M |
| Net Cash Per Share | $2.17 |
| Equity (Book Value) | 244.22M |
| Book Value Per Share | -174.15 |
| Working Capital | 277.83M |
Full Balance Sheet Cash Flow
In the last 12 months, operating cash flow was -$138.76 million and capital expenditures -$601,000, giving a free cash flow of -$139.36 million.
| Operating Cash Flow | -138.76M |
| Capital Expenditures | -601,000 |
| Depreciation & Amortization | 2.45M |
| Net Borrowing | -6.85M |
| Free Cash Flow | -139.36M |
| FCF Per Share | -$1.09 |
Full Cash Flow Statement Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |